New-onset type 1 diabetes and Graves' disease after antiretroviral therapy in a patient with human immunodeficiency virus infection.
Maho TaguchiNoriko Ihana-SugiyamaDaisuke ShiojiriKazuo IzumiMichi KobayashiNoriko KodaniRyotaro BouchiMitsuru OhsugiAkiyo TanabeKohjiro UekiHiroshi KajioPublished in: Journal of diabetes investigation (2023)
Patients with human immunodeficiency virus (HIV) infection receiving antiretroviral therapy can develop autoimmune diseases, referred to as immune-inflammatory reconstitution syndrome. Nevertheless, only a few reports on the onset of type 1 diabetes as immune-inflammatory reconstitution syndrome are available. A 40-year-old Japanese man with HIV infection was initiated with antiretroviral therapy at the age of 29 years. He developed Graves' disease at 35 years and diabetes, with a hemoglobin A1c of 6.5%, and maintained insulin secretion at 38 years. His antiglutamic acid decarboxylase antibody level was >2,000 U/mL, and he was diagnosed with slowly progressive type 1 diabetes. At the age of 40 years, he was admitted to our hospital with diabetic ketosis. We retrospectively assayed his stored plasma samples for thyroid-stimulating hormone receptor antibody and antiglutamic acid decarboxylase antibody, which showed positive conversion after initiating antiretroviral therapy, suggesting that Graves' disease and type 1 diabetes developed as a probable result of immune-inflammatory reconstitution syndrome.
Keyphrases
- antiretroviral therapy
- human immunodeficiency virus
- type diabetes
- hiv infected
- hiv positive
- hiv infected patients
- hiv aids
- glycemic control
- case report
- cardiovascular disease
- oxidative stress
- insulin resistance
- multiple sclerosis
- hepatitis c virus
- endothelial cells
- adipose tissue
- emergency department
- skeletal muscle
- room temperature
- ionic liquid